StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) shareholders

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$423.96−3.43 (-0.80%)

Close on Nov 16, 2026Market cap $9.80BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
24M of 23M shares
Institutional holders
413
79 new, 41 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
5 buys · 178 sales
Net sold $34.43M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Baker Bros. Advisors LP
Joint filing with Baker Bros. Advisors (GP) LLC (9.99%), Julian C. Baker (9.99%) and 1 more
2,330,1449.99%13D (active) amendmentNov 6, 2026
Behzad Aghazadeh
Joint filing with Avoro Capital Advisors LLC (9.90%)
2,288,8889.90%13G (passive) amendmentDec 31, 2023
Julian C. Baker
Joint filing with Baker Bros. Advisors LP (9.99%), Baker Bros. Advisors (GP) LLC (9.99%) and 1 more
2,070,5449.99%13D (active) amendmentMar 21, 2024
Janus Henderson Group PLC2,018,6478.80%13G (passive) amendmentMar 31, 2026
Roderick Wong, M.D
Joint filing with RTW Investments, LP (9.20%)
1,993,6879.20%13G (passive)Sep 30, 2024
Rebecca Taub, M.D.1,814,8317.80%13D (active) amendmentDec 10, 2025
Paul A Friedman, M.D.1,814,8317.80%13D (active) amendmentDec 10, 2025
Paulson & Co. Inc.1,392,1886.10%13G (passive) amendmentMar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MDGLValueChange% of portfolio
Baker Bros. Advisors LP2,143,1319.28%$1.15B+1,4305.77%
Rtw Investments, LP1,993,6878.63%$1.07B–9.14%
Jupiter Topco LLC1,936,0998.38%$1.04BNew0.42%
Avoro Capital Advisors LLC1,833,3337.94%$984.41M+15,1528.84%
Paulson & Co. Inc.1,340,0205.80%$719.52M−52,16827.94%
BlackRock, Inc.1,200,7705.20%$644.75M−359,1950.01%
Vanguard Capital Management LLC835,6683.62%$448.71M+8,5240.01%
Wellington Management Group Llp825,7143.57%$443.37M+130,7560.08%
Vanguard Portfolio Management LLC781,7313.38%$419.75M−59,4140.02%
State Street Corp527,0572.28%$283.00M−82,4680.01%
Citadel Advisors LLC507,2332.20%$272.36M+53,3900.03%
UBS Group AG401,7081.74%$215.70M+283,9290.03%
Geode Capital Management, LLC374,8801.62%$201.34M−80,9900.01%
FMR LLC356,2011.54%$191.26M−155,5270.01%
William Blair Investment Management, LLC324,1231.40%$174.04M−16,3960.52%
Invesco Ltd.301,4351.30%$161.86M−28,0840.01%
Armistice Capital, LLC288,0001.25%$154.64M+23,4171.89%
Lord, Abbett & Co. LLC281,5001.22%$151.15M+38,7740.43%
Assenagon Asset Management S.A.248,4281.08%$133.39M+232,3950.08%
Goldman Sachs Group Inc246,2801.07%$132.24M−31,0910.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202641324M100.0%79 / 144131 / 415M3M
Q1 202638024M100.0%63 / 130130 / 644M2M
Q4 202538724M100.0%85 / 137113 / 412M2M
Q3 202535223M100.0%87 / 107107 / 373M3M
Q2 202530524M100.0%38 / 107110 / 512M2M
Q1 202532124M100.0%73 / 11091 / 322M1M
Q4 202428323M99.4%67 / 9577 / 372M2M
Q3 202425723M98.4%45 / 8683 / 433M2M
Q2 202425723M99.2%49 / 11164 / 554M2M
Q1 202426622M94.5%74 / 8778 / 334M3M
Q4 202322620M86.5%56 / 9257 / 325M2M
Q3 202320517M75.2%37 / 8954 / 384M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

372 funds held MDGL in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MDGLValue% of fundAs of
Vanguard Total Stock Market Index Fund584,9972.53%$314.11M0.01%Jun 30, 2026
Vanguard Health Care Fund563,1172.44%$263.16M0.69%Jul 31, 2026
Vanguard Small-Cap Index Fund423,1421.83%$227.21M0.12%Jun 30, 2026
Janus Henderson Forty Fund338,6021.47%$181.81M0.76%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund243,6831.05%$130.85M0.28%Jun 30, 2026
Janus Henderson Enterprise Fund233,2691.01%$125.25M0.56%Jun 30, 2026
Vanguard Extended Market Index Fund216,8820.94%$116.45M0.12%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF211,2510.91%$113.43M1.06%Jun 30, 2026
Vanguard Explorer Fund190,1400.82%$88.86M0.40%Jul 31, 2026
Janus Henderson Contrarian Fund168,2590.73%$90.35M1.65%Jun 30, 2026
iShares Biotechnology ETF153,7360.67%$82.55M0.91%Jun 30, 2026
Janus Henderson Global Life Sciences Fund145,3640.63%$78.05M1.34%Jun 30, 2026
Lord Abbett Growth Leaders Fund140,4360.61%$65.63M0.88%Jul 31, 2026
Invesco Discovery Fund119,1970.52%$59.27M0.76%May 31, 2026
iShares Russell Mid-Cap Growth ETF105,7790.46%$56.80M0.26%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
William John SiboldPresident and CEO, Director202,8010.88%Sep 11, 2026
Shannon T. KelleyGeneral Counsel10,3970.05%Nov 6, 2026
David SoergelChief Medical Officer10,0330.04%Jun 1, 2026
Carole HuntsmanChief Commercial Officer12,6920.05%Mar 6, 2026
Mardi DierEVP and CFO12,8500.06%Mar 6, 2026
Rita ThakkarChief Accounting Officer2,3980.01%Jan 20, 2026
Robert E. WaltermireSenior VP, Chief Pharma Dev.10,9180.05%Mar 7, 2025
667, L.P.Director1,669,0167.22%Nov 6, 2026
Bros. Advisors Lp BakerDirector2,040,6828.83%Nov 6, 2026
Julian BakerDirector1,612,3396.98%Nov 6, 2026
Felix BakerDirector1,843,4697.98%Nov 6, 2026
Brothers Life Sciences LP BakerDirector1,948,8768.44%Nov 6, 2026
Bros. Advisors (GP) LLC BakerDirector1,947,9688.43%Nov 6, 2026
John C. ReedDirector6470.00%Aug 18, 2026
Daniel J. BrennanDirector1,3710.01%Jun 18, 2026
Rebecca TaubDirector1,108,2074.80%Jun 18, 2026
Jacqualyn A. FouseDirector1,5510.01%Jun 18, 2026
Richard S. LevyDirector22,4690.10%Jun 18, 2026
James M. DalyDirector3,0810.01%Jun 18, 2026
Paul A. FriedmanDirector855,8843.70%Jan 13, 2026
Kenneth BateDirector8,8960.04%Nov 7, 2025
Fred B. CravesDirector390,0281.69%Mar 14, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Shannon T. Kelley
General Counsel
Nov 6, 2026Sale(10b5-1 plan)−1,077$400.00$430.80K10,397
Bros. Advisors Lp Baker
Director
Nov 6, 2026Buy+2,000$396.61$793.22K2,040,682
Bros. Advisors Lp Baker
Director
Nov 6, 2026Buy+13,740$388.29$5.34M2,038,682
Bros. Advisors Lp Baker
Director
Nov 6, 2026Buy+60,400$383.01$23.13M2,024,942
Bros. Advisors Lp Baker
Director
Nov 4, 2026Buy+10,080$368.11$3.71M1,964,542
Bros. Advisors Lp Baker
Director
Nov 4, 2026Buy+5,586$366.99$2.05M1,954,462
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−106$534.06$56.61K202,801
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−120$546.38$65.57K197,746
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−761$544.83$414.62K197,866
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−1,539$544.02$837.25K198,627
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−1,202$542.60$652.21K200,166
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−368$541.64$199.32K201,368
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−687$540.59$371.39K201,736
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−160$537.62$86.02K202,423
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−218$535.94$116.83K202,583
William John Sibold
President and CEO, Director
Sep 11, 2026Sale(10b5-1 plan)−60$533.09$31.99K202,907
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−362$541.65$196.08K203,127
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−505$540.19$272.80K203,489
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−215$539.03$115.89K203,994
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−520$538.30$279.92K204,209
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−640$537.17$343.79K204,729
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−1,040$536.11$557.55K205,369
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−644$535.27$344.71K206,409
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−396$534.20$211.54K207,053
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−512$533.09$272.94K207,449
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−368$531.99$195.77K207,961
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−522$530.23$276.78K208,329
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−347$529.27$183.66K208,851
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−131$527.88$69.15K209,198
William John Sibold
President and CEO, Director
Sep 9, 2026Sale(10b5-1 plan)−160$542.55$86.81K202,967
Shannon T. Kelley
General Counsel
Aug 17, 2026Sale−664$514.97$341.94K11,474
John C. Reed
Director
Aug 15, 2026Award+647––647
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−140$542.75$75.99K211,689
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−110$543.79$59.82K211,579
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−275$545.71$150.07K210,759
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−269$547.08$147.16K210,490
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−680$547.70$372.44K209,810
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−47$548.87$25.80K209,763
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−153$550.01$84.15K209,610
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−1$550.72$551209,609
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−280$555.05$155.41K209,329
William John Sibold
President and CEO, Director
Jul 20, 2026Sale−545$544.71$296.87K211,034
William John Sibold
President and CEO, Director
Jul 17, 2026Option exercise+50,000––211,829
Daniel J. Brennan
Director
Jun 17, 2026Award+404––1,371
James M. Daly
Director
Jun 17, 2026Award+454––3,081
Richard S. Levy
Director
Jun 17, 2026Award+454––22,469
Jacqualyn A. Fouse
Director
Jun 17, 2026Award+454––1,551
Brothers Life Sciences LP Baker
Director
Jun 17, 2026Award+908––1,948,876
Brothers Life Sciences LP Baker
Director
Jun 17, 2026Award+908––203,721
Rebecca Taub
Director
Jun 17, 2026Award+454––452,667
David Soergel
Chief Medical Officer
Jun 1, 2026Sale(10b5-1 plan)−1,042$495.74$516.56K10,033
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−320$508.24$162.64K27,337
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−40$506.68$20.27K27,657
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−151$510.36$77.06K27,186
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−610$511.40$311.95K26,576
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−439$512.50$224.99K26,137
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−40$512.97$20.52K26,097
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−343$514.67$176.53K25,754
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−657$515.92$338.96K25,097
Richard S. Levy
Director
May 22, 2026Sale(10b5-1 plan)−723$516.87$373.70K24,374

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.71%
2M shares short
Days to cover
7.6
At 0M shares a day
Change since last report
-2.6%
From 2M shares
Short volume, 20 days
55.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Madrigal Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,700 shares on Oct 7, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Shannon T. Kelley
Officer
Nov 6, 20261,077$430.91KNov 6, 2026Restricted Stock Units
Paul A. Friedman
Director
Sep 28, 202650,000$25.83MSep 28, 2026Exercise of Stock Options
William John Sibold
Director, Officer
Sep 11, 20265,221$2.78MSep 11, 2026Restricted Stock Units
William John Sibold
Officer and Director
Sep 9, 20266,362$3.40MSep 9, 2026Restricted Stock Unit Grant
Shannon T. Kelley
Officer
Aug 20, 2026664$337.02KAug 17, 2026Restricted Stock Unit Grant
William John Sibold
Officer and Director
Jul 20, 20262,500$1.38MJul 20, 2026Performance Restricted Stock Unit Grant
David Soergel
Officer
Jun 1, 20261,042$518.16KJun 1, 2026Restricted Stock Units
Richard S. Levy
Director
May 22, 20265,682$2.92MMay 22, 2026Previously Exercised Stock Options
David Soergel
Officer
May 18, 2026844$441.99KMay 18, 2026Restricted Stock Unit Grant
Shannon T. Kelley
Officer
Mar 6, 2026360$158.16KMar 6, 2026Restricted Stock Unit Grant
Carole Huntsman
Officer
Mar 6, 2026419$184.08KMar 6, 2026Restricted Stock Unit Grant
William John Sibold
Officer and Director
Mar 6, 20261,663$730.62KMar 6, 2026Restricted Stock Unit Grant
Mardi Dier
Officer
Mar 6, 2026646$283.81KMar 6, 2026Restricted Stock Unit Grant
Rebecca Taub
Director
Mar 6, 2026491$215.72KMar 6, 2026Restricted Stock Unit Grant
Mardi Dier
Officer
Mar 6, 20261,336$586.96KMar 6, 2026Restricted Stock Units

See a number that looks wrong?